Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    AMG479
Show Display Options
Rank Status Study
21 Terminated
Has Results
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479;   Drug: AMG 479 Placebo
22 Completed Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
Condition: Pancreatic Cancer
Interventions: Biological: ganitumab;   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy
23 Completed AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Prostate Cancer;   Sarcoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: ganitumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy
24 Completed
Has Results
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Condition: Metastatic Colorectal Cancer
Interventions: Biological: Panitumumab;   Biological: Ganitumab;   Drug: Irinotecan
25 Withdrawn Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: ganitumab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo;   Other: questionnaire administration
26 Recruiting I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Tumors
Interventions: Drug: Standard Therapy;   Drug: AMG 386 with or without Trastuzumab;   Drug: AMG 479 (Ganitumab) plus Metformin;   Drug: MK-2206 with or without Trastuzumab;   Drug: AMG 386 and Trastuzumab;   Drug: T-DM1 and Pertuzumab;   Drug: Pertuzumab and Trastuzumab;   Drug: Ganetespib;   Drug: ABT-888;   Drug: Neratinib;   Drug: PLX3397;   Drug: Pembrolizumab;   Drug: Talazoparib plus Irinotecan

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-26) Next Page   
Indicates status has not been verified in more than two years